The duration of use of Upadacitinib needs to be dynamically adjusted based on indications and individual efficacy. It is generally recommended to use it for a long time with sustained effectiveness and tolerability, and the specific course of treatment should be strictly evaluated according to medical advice.

Differences in treatment courses for different indications

(1) Rheumatoid arthritis: Continuous medication is needed to control symptoms, and most patients require several years or even lifelong use, with regular assessment of joint injury progression.

(2) Atopic dermatitis: Moderate to severe patients may need to continue medication for 1-3 years, and after symptoms improve, they can try to gradually reduce their dosage.

2 key factors affecting the course of treatment

(1) Efficacy evaluation: Inflammatory indicators and clinical symptoms should be rechecked every 3-6 months, and if ineffective, the plan should be adjusted.

(2) Safety monitoring: Long term use requires regular checks on infection indicators, blood lipids, and liver function. Treatment may be interrupted in case of abnormalities.

3. Medication time limits for special populations

(1) Elderly patients: may need to shorten the course of treatment or reduce the dosage to reduce the risk of opportunistic infections.

(2) Patients with chronic diseases, such as diabetes and latent infection of tuberculosis, need to carefully evaluate the risk ratio of long-term drug benefit.